[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Senegal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":376},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,79,106,160,182,200,216,234,258,293,324,356],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642705","holistic-approach-supporting-the-uptake-of-innovative-diagnostic-technologies-for-respiratory-infections-100642705",false,"NCT07651865","Holistic Approach Supporting the Uptake of Innovative Diagnostic Technologies for Respiratory Infections","Clinical Validation of Novel Microfluidic and Lateral Flow-based Technologies for the Detection of Lower and Upper Respiratory Tract Infections - HOLICARE Trial","HOLICARE","Inclusion Criteria:\n\n* Age ≥ 6 months\n* Presentation with suspected respiratory tract infection and at least two of the following symptoms:\n* Fever (axillary temperature ≥37.5°C) or history of fever\n* New acute cough episode\n* Shortness of breath\n* Tachypnoea (fast breathing)\n* Loss of smell and\u002For taste\n* Ability to provide written informed consent (or assent with parent\u002Fguardian consent for minors)\n* For infants (≤1 year), both fever and new acute cough must be present at screening\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\u002Fassent\n* Refusal to provide study samples\n* Severe chronic medical conditions or mental incapacity that, in the opinion of the clinician, would interfere with study participation\n* Hospitalisation within the previous 2 weeks for reasons unrelated to the current respiratory symptoms\n* Acute injury, trauma, or poisoning interfering with participation\n* Chronic cough lasting \\>2 weeks, unless tuberculosis is suspected in the LRTI cohort\n* Antibiotic use within the previous 2 weeks for participants enrolled in the LRTI cohort (Sub-study 2) only","ALL","6 Months",{"count":20,"type":21},2160,"ESTIMATED","OBSERVATIONAL","This observational diagnostic validation study aims to evaluate the clinical performance of novel lateral flow and microfluidic-based technologies for the detection of upper and lower respiratory tract infections in children and adults presenting with respiratory symptoms in Uganda, Ethiopia, and Senegal. The main questions it aims to answer are:\n\n1. whether the novel multiplex lateral flow tests and point-of-care microfluidic platform demonstrate sufficient sensitivity and specificity for detecting respiratory pathogens compared with standard laboratory reference methods, and\n2. whether these technologies are feasible and usable in low-resource clinical settings.\n\nParticipants presenting with suspected respiratory tract infections as part of routine clinical care will provide respiratory and blood samples for diagnostic testing and biobanking, and demographic and clinical information will be collected during a single study visit. Some adult participants and community stakeholders will also complete surveys or interviews regarding the acceptability of biobanking and diagnostic implementation.",[25,26],"Upper Respiratory Infection","Lower Resp Tract Infection",[28,29,30,31,32,33],"Point of Care","POC","Later Flow Test (LFT)","Global Health","Rapid diagnostic","Microfluidics","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2025-04-07",{"date":42,"type":21},"2026-08-31",{"name":44,"class":45},"Karolinska Institutet","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100644093","phase-3-optimizing-the-use-of-aspirin-for-the-prevention-of-preeclampsia-100644093","NCT07665853","Optimizing the Use of Aspirin for the Prevention of Preeclampsia","Optim-PRE","Inclusion Criteria:\n\n* Age 18 years or older at time of enrollment.\n* Singleton pregnancy.\n* Ability to read and understand the informed consent form.\n* Having undergone first-trimester preeclampsia screening between 11+0 and 13+6 weeks of gestation using a validated multiparametric algorithm (FMF algorithm at a risk cutoff of 1:100, or Gaussian algorithm at a cutoff of 1:170) and being classified as high risk for preterm preeclampsia.\n* Currently taking aspirin 150 mg\u002Fday initiated after first-trimester high-risk classification, in accordance with standard clinical practice.\n* Voluntary signing of the informed consent form and willingness to comply with the study requirements, including acceptance of the assigned aspirin treatment duration, additional blood tests, and additional ultrasound assessments.\n\nExclusion Criteria:\n\n* Early pregnancy loss, intrauterine fetal death, or fetus with major structural malformations diagnosed at the time of enrollment.\n* Fetus affected by a known genetic or chromosomal disease.\n* Contraindication, allergy, or intolerance to aspirin (acetylsalicylic acid).\n* Any medical condition that makes aspirin discontinuation unsafe or impossible (e.g., antiphospholipid syndrome, mechanical heart valve, or other conditions requiring indefinite antiplatelet or anticoagulant therapy).","FEMALE","18 Years",{"count":57,"type":21},15160,"INTERVENTIONAL",[60],"PHASE3","Pregnant women at higher risk for preeclampsia (PE) are currently recommended to take low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation. High-risk women are identified through a multiparametric first-trimester screening that combines maternal history, blood pressure, uterine artery blood flow, and placental growth factor (PlGF). Although this screening effectively identifies women at risk, the majority of those classified as high risk will not develop PE. As a result, a large proportion of pregnant women receive prolonged aspirin treatment without benefit, while remaining exposed to its potential side effects, including increased bleeding risk.\n\nAspirin prevents PE primarily by improving placental development during the first half of pregnancy. Whether continuing ASA beyond 24-28 weeks provides additional protection remains unclear. A previous randomized trial demonstrated that stopping ASA at 24-28 weeks was non-inferior to continuing until 36 weeks in a predominantly European population. However, whether this finding applies to more diverse populations, including women of African origin who carry a substantially higher baseline risk of PE, has not been established.\n\nThis is a multicenter, randomized, open-label, parallel-group, phase III non-inferiority trial conducted across sites in Europe and Africa. A total of 15,160 pregnant women at high risk for PE from first-trimester screening, currently under ASA treatment, will be randomized in a 1:1 ratio before 28 weeks of gestation to either discontinue ASA at 24-28 weeks or continue ASA until 36 weeks of gestation.",[63],"Preeclampsia",[63,65,66,67,68],"First Trimester Screening","Placental Growth Factor","Ophthalmic Artery Doppler","Acetyl Salicylic Acid (ASA)","NOT_YET_RECRUITING","2026-06-18",{"date":35,"type":38},{"date":73,"type":21},"2026-07-01",{"date":75,"type":21},"2028-05",{"name":77,"class":45},"Hospital Universitari Vall d'Hebron Research Institute",38,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":58,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100481060","adaptation-and-implementation-of-a-patient-navigation-program-for-cervical-cancer-screening-across-contexts-in-senegal-100481060","NCT05544084","Adaptation and Implementation of a Patient Navigation Program for Cervical Cancer Screening Across Contexts in Senegal","Inclusion Criteria:\n\nThe inclusion criteria for samples a, b, \\& c are as follows:\n\n1\\) Senegal citizen between the ages of 25 and 69, 2) willing to participate in survey assessments;\n\nThe additional criteria apply for both women and men for the follow samples:\n\nSample a: 3) an invited member of the study National Advisory Board or Regional Implementation Resource Teams as defined above; 4) able to read and write in French.\n\nSample b: 3) employed by the state at a study site health facility as a patient navigator, clinician (nurse, midwife) who treats and educates patients, or is a community health worker at the facility or community level (Bajenu Gox - women's health educator).\n\nSample c: Women: 3) a woman living with a male partner who also agrees to participate in the study, 4) eligible to seek cervical cancer prevention services at a designated health facility in Senegal. Men: 3) a man living in a household with at least one woman eligible to seek cervical cancer prevention services at a designated health facility in Senegal.\n\nExclusion Criteria:\n\n* No additional exclusion criteria exist.",true,"25 Years","69 Years",{"count":89,"type":21},901,[91],"NA","The goal of this project is to prevent unnecessary deaths due to cervical cancer in Senegal. This mixed methods research responds to identified intrapersonal- and community-level barriers to early cervical cancer screening uptake, follow-up, and treatment among women there. Investigators will apply the Dynamic Adaptation Process (DAP) as integrated into the Exploration, Preparation, Implementation, Sustainment (EPIS) framework to study the adaptation of an evidence-based cervical cancer patient navigation program in urban and rural contexts in Senegal, measure the intervention effectiveness, and evaluate programmatic implementation outcomes. By studying the process of adaptation of a patient navigation program in a low- and middle-income country (LMIC), investigators will build new knowledge while addressing an important public health issue. The project demonstrates innovation by advancing both adaptation and implementation process knowledge of an evidence-based patient navigation intervention in various contexts within a LMIC with a particular focus on how the adaptation responds to cancer-related stigma, misinformation, and women's autonomy in healthcare decision-making. Investigators will build knowledge through local learning which will further the long-term goal to inform the national cervical cancer prevention and control programs in two areas of Senegal and other similar LMICs.",[94,95],"Cervical Cancer","Behavior","2026-05-06",{"date":98,"type":38},"2026-05-08",{"date":100,"type":38},"2023-08-01",{"date":102,"type":21},"2027-08-28",{"name":104,"class":45},"University of Illinois at Chicago",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":58,"phases":117,"briefSummary":118,"conditions":119,"keywords":133,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100631921","early-detection-and-ai-based-management-of-skin-related-neglected-tropical-diseases-in-sub-saharan-africa-by-frontline-health-workers-100631921","NCT07506967","Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers","Early Detection and Management of SKIN-related negleCted Tropical Diseases Using Artificial Intelligence in Sub-saharan afRica (SkincAIr)","SkincAIr","1. Frontline Health Workers (FHWs) Age Group\n\n   * Age Range: 18 years and above o Justification: FHWs must be adults, legally eligible to provide healthcare services and consent to participate in the study Sex Distribution\n   * Male and Female FHWs o Justification: Both male and female FHWs will be included to reflect the actual workforce distribution and to ensure generalizability of the results across genders.\n\n   Inclusion criteria for FHWs:\n   1. Professional Role:\n\n      o Must be working as a FHW at one of the selected health centers at the time of the validation study.\n\n      ▪ Justification: The study aims to assess the diagnostic performance of those directly involved in primary patient care in the targeted settings.\n   2. Willingness to Participate:\n\n      o Willing to provide written informed consent to participate in the study.\n\n      ▪ Justification: Ethical standards require voluntary participation with informed consent.\n   3. Smartphone Usage:\n\n      o Willing and able to use a smartphone during the study.\n\n      ▪ Justification: The SkincAIr app is smartphone-based; therefore, FHWs must be willing to use and have access to such devices.\n   4. No Specialized Dermatology Training:\n\n      * FHWs without specialised training in dermatology or extensive experience in skin disease diagnosis.\n\n        * Justification: The study aims to evaluate the app's effectiveness among generalist healthcare workers who would benefit most from diagnostic support tools.\n\n   Exclusion criteria for FHWs:\n\n   1\\. Prior Specialised Training in dermatology:\n\n   o FHWs with formal education or extensive experience in dermatology.\n   * Justification: Including specialists could skew results, as their baseline diagnostic accuracy may already be high, reducing the observable impact of the app.\n\n     2\\. Refusal or Inability to Consent:\n     * FHWs unwilling or unable to provide written informed consent.\n   * Justification: Ethical compliance requires informed consent for participation. 3. Inability to Use the App: o FHWs unable to use a smartphone due to technical limitations, physical impairments, or lack of familiarity with the technology.\n   * Justification: Effective use of the app is essential for the intervention; inability to use it would prevent meaningful participation.\n2. Patients with Skin complaints Size\n\n   ● Total Patients: \\~750 patients Age Group\n\n   ● All Age Groups:\n\n   o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan.\n\n   Sex Distribution\n   * Male and Female Patients\n   * Justification: Both sexes are included to capture the full spectrum of the disease burden and ensure the app's diagnostic accuracy is effective regardless of sex.\n\n   Inclusion Criteria for Patients with Skin complaints:\n\n   1\\. Presenting with Skin Complaints:\n\n   o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition.\n   * Justification: The study aims to evaluate the app's effectiveness in real-world conditions, including all patients with potential skin-NTDs 2. Willingness to Participate: o Patients (or guardians, in the case of minors) willing to provide written informed consent for participation.\n   * Justification: Ethical standards require informed consent from patients or their legal guardians.\n\n     3\\. Ability to Comply with Study Procedures:\n\n     o Patients are able to follow study instructions and attend necessary follow-up appointments.\n   * Justification: Ensures complete data collection and accurate assessment of outcomes.\n\n     4\\. Patients with Co-morbid conditions:\n   * Justification: Immunosuppression that occurs in some comorbid conditions e.g. HIV\u002FAIDS or severe malnutrition can reveal the Skin disease and can affect both the clinical progression and even severity of the Skin NTD. This also includes patients with multiple skin-NTDs.\n\n   Exclusion Criteria for Patients with Skin complaints:\n   1. Refusal or Inability to Consent:\n\n      o Patients (or guardians) unwilling or unable to provide written informed consent.\n\n      ▪ Justification: Ethical compliance requires informed consent for participation.\n   2. Non-Skin-Related Complaints:\n\n      o Patients presenting with complaints unrelated to skin conditions.\n\n      ▪ Justification: The study focuses on skin-NTDs; including unrelated cases would not contribute to the study objectives.\n   3. Previous Participation in the Study:\n\n      o Patients who have already participated in the study.\n\n      ▪ Justification: To avoid duplicate data and potential bias in outcomes.\n\n      Additional Considerations:\n\n      Diversity and Representation ● Geographical Diversity:\n\n      o Including health centres from different regions within each country ensures that the findings are representative of various settings (urban, peri-urban, rural).\n\n      ● Cultural and Socioeconomic Factors:\n\n      o The study acknowledges that cultural beliefs and socioeconomic status may influence healthcare-seeking behaviour and disease presentation. By including a diverse patient population, the study aims to capture these variations.\n\n      Ethical Justification ● Inclusivity:\n      * Including all age groups and both sexes aligns with ethical principles of justice and fairness, ensuring that the benefits of the research are accessible to all segments of the population.\n\n        * Vulnerable Populations:\n      * While including minors and potentially vulnerable adults, the study will implement additional safeguards to protect their rights and well-being, following ethical guidelines and obtaining consent from guardians when necessary.","0 Years",{"count":116,"type":21},2420,[91],"Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making diagnosis difficult. To address this challenge, the SkincAIr project is testing whether a mobile app powered by artificial intelligence (AI) can help FHWs improve their ability to detect Skin NTDs. The study will be conducted in two arms. In the first clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions that will be used for development and training of the AI model within the SkincAIr app before it is tested among FHWs. The second validation study arm will take place in 3 countries (Kenya, Ethiopia and Senegal), and will involve 50 FHWs and around 750 patients in each country over 24 months. During the first 12 months (Phase A), FHWs will diagnose patients using standard methods without the app, establishing baseline performance on key indicators including diagnostic accuracy, time to diagnosis, referral patterns, and cost implications of improved primary-level diagnosis. For the following 6 months (Phase B), FHWs will use the SkincAIr app with AI functionality activated to support diagnosis and enable real-time geolocated disease mapping and hotspot identification. In the final 6 months (Phase C), the app is withdrawn to assess whether FHWs retain their improved diagnostic skills. We will summarize the results using simple numbers and charts to show how often things happen and what the average results look like. Researchers will evaluate how well the app improves diagnosis by FHWs and whether FHWs retain their improved skills even after AI support is removed, by comparing their results with those of a skin specialist (dermatologist). Interviews and group discussions will be recorded, written down, organized into key ideas, and carefully reviewed using a computer program to understand the main themes. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to relevant institutional and regulatory authorities. If successful, this AI tool could boost early detection of skin diseases, enhance disease tracking, and improve healthcare in underserved areas.",[120,121,122,123,124,125,126,127,128,129,130,131,132],"Skin and Connective Tissue Diseases","Neglected Tropical Diseases","Leprosy","Buruli Ulcer","Cutaneous Leishmaniasis","Scabies","Mycetoma","Lymphatic Filariasis","Onchocerciasis","Tungiasis","Post Kala-Azar Dermal Leishmaniasis","Yaws","Podoconiosis",[134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149],"Skin-related neglected tropical diseases","Artificial Intelligence","Mobile Health","mHealth","Frontline Health Workers","Diagnostic Accuracy","Sub-Saharan Africa","Skin NTDs","Digital Health","AI Diagnostic Tool","Capacity Building","Kenya","Ethiopia","Senegal","Nigeria","Democratic Republic of the Congo","2026-03-27",{"date":152,"type":38},"2026-04-02",{"date":154,"type":21},"2026-05-01",{"date":156,"type":21},"2030-05-31",{"name":158,"class":45},"Kenya Medical Research Institute",5,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":55,"enrollmentInfo":167,"targetDuration":169,"studyType":22,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":46},"100423472","recommendations-for-the-treatment-of-children-with-acute-lymphoblastic-leukemia-in-the-gfaop-100423472","NCT04794296","Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP","LALGFA2019","Inclusion Criteria:\n\nChildren 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2\n\n\\-\n\nExclusion Criteria:\n\nALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21",{"count":168,"type":21},500,"10 Years","The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G\u002FL or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.",[172],"Childhood ALL","2026-02-27",{"date":175,"type":38},"2026-03-02",{"date":177,"type":38},"2021-11-15",{"date":179,"type":21},"2030-12-31",{"name":181,"class":45},"French Africa Pediatric Oncology Group",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":55,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":199},"100395158","therapeutic-recommendations-for-the-treatment-of-children-with-a-retinoblastoma-100395158","NCT04425434","Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma","GFARB12019","Inclusion Criteria:\n\n* Unilateral intraocular Retinoblastoma (RB)\n* Unilateral extraocular intraorbital (RB)\n* Bilateral intraocular (RB)\n* bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.\n\nExclusion Criteria:\n\n* Externalized tumor mass\n* massive extension to optic nerve up to optical channeltumor\n* intracranial extension leptomeninges\n* cerebral parenchyma\n* extension to regional lymph nodes and\u002For remote metastases.\n* cerebrospinal fluid involvement.\n* Trilateral RB\n* Incapacity to followed the whole treatement.",{"count":190,"type":21},3000,"As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.",[193],"Retinoblastoma",{"date":175,"type":38},{"date":196,"type":38},"2020-11-01",{"date":179,"type":21},{"name":181,"class":45},7,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":55,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":215,"locationsCount":199},"100395157","recommendations-for-the-treatment-of-children-with-burkitts-lymphoma-100395157","NCT04425421","Recommendations for the Treatment of Children With Burkitt's Lymphoma","GFALMB2019","Inclusion Criteria:\n\nClinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.\n\n\\-\n\nExclusion Criteria:\n\nNot a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.",{"count":208,"type":21},1000,"This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.",[211],"Burkitt Lymphoma",{"date":175,"type":38},{"date":196,"type":38},{"date":179,"type":21},{"name":181,"class":45},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":199},"100395008","therapeutic-recommendations-for-nephroblastoma-100395008","NCT04423484","Therapeutic Recommendations for Nephroblastoma","Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.","GFANEPHRO20","Inclusion Criteria:\n\nUnilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.\n\n.\n\nExclusion Criteria:\n\nBilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal",{"count":208,"type":21},"The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.",[227],"Nephroblastoma",{"date":175,"type":38},{"date":230,"type":38},"2020-07-01",{"date":232,"type":21},"2030-12-30",{"name":181,"class":45},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":242,"maxAge":55,"enrollmentInfo":243,"targetDuration":245,"studyType":22,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -","1 Day",{"count":244,"type":21},10000,"12 Months","The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[248],"Pediatric Cancer","2025-09-29",{"date":251,"type":38},"2025-10-03",{"date":253,"type":38},"2016-01-01",{"date":255,"type":21},"2030-12",{"name":181,"class":45},14,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":58,"phases":270,"briefSummary":271,"conditions":272,"keywords":279,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100567641","novel-tools-to-improve-management-of-paediatric-community-acquired-pneumonia---toolcap-100567641","NCT06670833","Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP","ToolCAP: Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia","ToolCAP","Inclusion Criteria:\n\n* Cough OR Difficulty Breathing AND,\n* One of the below:\n\nFast breathing (tachypnoea) \\> 50\u002Fminute (2-12 months) \\> 40\u002Fminute (1-\\\u003C5 years) \\> 25\u002Fminute (5-12 years) OR Lower chest wall indrawing\n\nExclusion Criteria:\n\n* Presenting for repeat visit\u002Ffollow-up of a treated lower respiratory tract infection (index illness \u002F non-acute) or enrolled in the study within the preceding 28 days.\n* Received antibiotic treatment for more than 48 hours at the time of enrolment.\n* WHO IMCI danger signs (inability to drink\u002Fbreastfeed, vomiting everything, convulsions with this illness, lethargy\u002Funconscious).\n* Presence of jaundice.\n* Hypoxaemia with oxygen saturation (SpO2) \\\u003C88%\n* Oxygen saturation (SpO2) \\\u003C90% (or country-specific \u002F altitude-adjusted thresholds) i) With signs of severe respiratory distress (such as nasal flaring, grunting, etc.) OR ii) In children \\\u003C 6 months\n* Requiring non-invasive ventilatory support (i.e., high-flow, bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP))\n* Underlying disease associated with increased risk of severe pneumonia or pneumonia of unusual aetiology (e.g., WHO acute malnutrition requiring antibiotics as per local guidelines, severe immunodeficiency)\n* HIV positive participant that is either i) less than 12 months old; OR ii) requires admission for this illness; OR iii) known to be uncontrolled on treatment (with a documented VL \\>1000c\u002Fml in the previous 6 months)\n* Caregiver unavailable at the time of enrolment, or unwilling, to provide informed consent.","60 Days","12 Years",{"count":269,"type":21},3500,[91],"The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections. The study will also look at if it's possible to improve how doctors decide which children need antibiotics.\n\n* Lung infections are the most common reason for children to go to the clinic\u002Fhospital.\n* Doctors usually give an antibiotic to every child with a lung infection.\n* Lung infections can be caused by 2 different types of germs - bacteria or viruses.\n* Antibiotics only work against bacteria and not against viruses. Lung infections caused by viruses don't need antibiotics as the body fights them by itself.\n* Lots of research now shows that only 1 in 4 children with a lung infection actually needs an antibiotic, as the rest only have a viral infection causing the symptoms.\n* This means that 3 in 4 children get an antibiotic when they don't need it.\n* Taking too many antibiotics can cause problems for children as it can cause diseases like diabetes or asthma.\n* Nowadays, due to too many people using too many antibiotics, experts are starting to worry that bacteria are starting to become resistant (stronger than the antibiotic).\n* Ultrasound of the lungs appears to be a way of safely looking at the lungs to see if there is an infection and may help doctors better decide who needs an antibiotic.\n\nThis study includes children aged 2 months-12 years who come to the hospital with a lung infection. Children who are very unwell or who have already had 2 days of antibiotic treatment will not be allowed to be in the study.",[273,274,275,276,277,278],"Pneumonia","Pneumonia Childhood","Pneumonia - Bacterial","Pediatrics","LRTI","IMCI Guidelines",[280,281,282],"Lung ultrasound (LUS)","Lung auscultation","Pediatric pneumonia","2025-06-17",{"date":285,"type":38},"2025-06-18",{"date":287,"type":38},"2025-04-04",{"date":289,"type":21},"2026-12",{"name":291,"class":45},"University of Bern",9,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":85,"sex":17,"minAge":299,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":58,"phases":302,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100589093","optimizing-routine-delivery-of-essential-child-health-and-nutrition-package-through-primary-health-care-contacts-100589093","NCT06949930","OPTIMIZING ROUTINE DELIVERY OF ESSENTIAL CHILD HEALTH AND NUTRITION PACKAGE THROUGH PRIMARY HEALTH CARE CONTACTS","Inclusion Criteria:\n\n* Caregivers of children 12-59 months of age\n* Health service providers\n\nExclusion Criteria:\n\n\\- None","15 Years",{"count":301,"type":21},1928,[91],"The primary objective of the study is to assess whether optimization of an essential package of health and nutrition services for children under five years of age using vitamin A supplementation touch points (i.e., the implementation model) in selected areas in Kenya and Senegal will increase the coverage of vitamin A supplementation and the coverage of other child health and nutrition services. In addition, the study will also assess the feasibility of the implementation model and the drivers of coverage outcomes.",[305,306,307],"Coverage of Vitamin A Supplementation","Coverage of Immunization","Feasibility and Fidelity of Implementation",[309,310,311,312,313],"VAS","immunization","coverage","hybrid effectiveness-implementation research study","essential child health and nutrition services","2025-04-22",{"date":316,"type":38},"2025-04-29",{"date":318,"type":38},"2025-02-21",{"date":320,"type":21},"2027-03",{"name":322,"class":45},"Nutrition International",2,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":58,"phases":334,"briefSummary":335,"conditions":336,"keywords":340,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100424919","remote-ischaemic-conditioning-in-stemi-patients-in-africa-100424919","NCT04813159","Remote Ischaemic Conditioning in STEMI Patients in AFRICA","Remote Ischaemic Conditioning in STEMI Patients in AFRICA: The RIC-AFRICA Trial","RIC-AFRICA","We will be recruiting 3 different strata of STEMI patients.\n\n1. Adult patients (≥18 years old) presenting with STEMI receiving thrombolytic therapy within guideline-recommended time (i.e., within \\\u003C12 hours of most severe chest pain onset).\n2. Adult patients (≥18 years old) presenting with STEMI who are ineligible for thrombolysis because they present outside of guideline-recommended time (\\\u003C12 hours) but within 24 hours of most severe chest pain onset.\n3. Adult patients (≥18 years old) presenting with evidence of STEMI who do not receive thrombolysis and who present ≥24 hours and within 72 hours of most severe chest pain onset.\n\nInterventional arm of the Study: Randomized Control Trial\n\nPatients who are deemed eligible for randomization into the trial on account of presentation with STEMI within 24 hours, will be eligible for the interventional arm of the study if the following inclusion\u002Fexclusion criteria are met.\n\nInclusion Criteria\n\nI. Adult patients (≥18 years old) presenting with suspected STEMI (ST-elevation at the J-point in two contiguous leads ( ≥ 0.2mV in men or ≥ 0.15mV in women in leads V2-V3 and\u002For ≥ 0.1mV in other lead); and II. Within 24 hours of onset of myocardial infarction as deemed by the attending clinician; and III. Signed informed consent.\n\nExclusion criteria\n\nI. STEMI patients due to undergo primary percutaneous coronary intervention;\n\nII. STEMI patients presenting with cardiogenic shock or haemodynamic instability as defined by: systolic blood pressure (SBP) measurement of \\\u003C90 mm Hg for ≥30 minutes; or use of pharmacological and\u002For mechanical support to maintain SBP ≥ 90 mm Hg; and evidence of end-organ damage defined by: urine output of \\\u003C30 mL\u002Fh; altered mental status; and\u002For serum lactate \\>2.0 mmol\u002FL;\n\nIII. Contraindications for the use of RIC or sham-control on either arm such as:\n\n1. severe active skin disease\u002Fburns on both arms; or\n2. bilateral upper limb amputations; or\n3. evidence of acute limb ischaemia on either arm; or\n4. active upper limb gangrene of any digits;\n5. breast cancer with lymph-node involvement on the ipsilateral side of RIC; or\n6. bilateral arteriovenous fistulae needed for haemodialysis.\n\nIV. Inter-current disease with an expected life expectancy of less than 24 hours;\n\nV. Contra-indication to thrombolytic therapy in patients presenting within guideline-recommended time (\\\u003C12 hours).\n\nObservational arm of the study\n\nPatients who are deemed ineligible for randomization into the trial on account of presentation beyond 24 hours, will be eligible for the observational arm of the study if the following inclusion\u002Fexclusion criteria are met.\n\nInclusion Criteria\n\nI. Signed informed consent; and\n\nII. Clinical evidence of STEMI older than 24 hours and less than 72 hours as defined by:\n\n1. Compatible history with maximal chest pain between 24 -72 hours prior to presentation; and\n2. Compatible biomarkers (elevated cardiac troponin); and\n3. ECG compatible with recent STEMI; and\u002For\n4. Compatible echocardiography.\n\nExclusion criteria\n\nI. Refusal or inability to sign informed consent.",{"count":333,"type":21},1400,[91],"The RIC-AFRICA trial is a multi-centre, sham-controlled, randomised controlled trial (RCT) involving 1400 ST-segment elevation myocardial infarction (STEMI) patients presenting within ≤ 24 hours of myocardial infarction (MI) onset, across approximately 25 sites in 7 African countries (South Africa, Kenya, Sudan, Uganda, Mozambique, Senegal and Mauritius). Patients presenting with STEMI and deemed ineligible for the RIC AFRICA RCT because they present \\>24 hours from MI onset but less than 72 hours, will be recruited into the observational arm of the study with the same endpoints as the trial. The purpose of the RCT is to determine whether Remote Ischaemic Conditioning (RIC) can reduce the rates of all-cause death and early post-myocardial heart failure at 30-days in STEMI patients treated predominantly with thrombolytic therapy.",[337,338,339],"STEMI","Remote Ischaemic Conditioning","Myocardial Reperfusion Injury",[341,342,343,344,338,345,337],"Cardioprotection","Ischaemia\u002Freperfusion injury","ST-Elevation myocardial infarction","Hospitalisation for post-myocardial infarction heart failure","Cardiovascular mortality","2025-03-31",{"date":348,"type":38},"2025-04-03",{"date":350,"type":38},"2022-01-12",{"date":352,"type":21},"2027-12-31",{"name":354,"class":45},"University of Cape Town",20,{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":323},"100555486","mycetoma-retrospective-data-collection-100555486","NCT06512714","Mycetoma Retrospective Data Collection","Estimating the Burden of Mycetoma: A Retrospective Analysis of Hospital Records","Inclusion Criteria:\n\n* Any patient given a diagnosis of mycetoma in a medical, radiologic, or laboratory record.\n\nExclusion Criteria:\n\n* Patients with illegible or inaccessible health records.",{"count":364,"type":21},1600,"The goal of this retrospective observational study is to describe mycetoma cases detected in health care facilities in India and Senegal in a 10-year period. The main objectives are to:\n\n* Determine the number of mycetoma cases diagnosed per year and trends over time.\n* Describe characteristics of diagnosed mycetoma cases.\n\n  1. Describe demographic characteristics of patients with mycetoma.\n  2. Describe clinical characteristics of patients with mycetoma upon initial presentation and over time.\n* Assess etiology of mycetoma cases.\n* Characterize clinical management of mycetoma cases.\n\n  1. Characterize approaches to diagnosis of mycetoma.\n  2. Investigate types and durations of treatments (including medical and surgical approaches) utilized to treat mycetoma cases.\n  3. Describe clinical outcomes among patients with mycetoma.\n\nThe study team will review all available medical, laboratory and radiologic records of identified mycetoma cases and use data collection forms to extract relevant data.",[126],"2024-07-31",{"date":369,"type":38},"2024-08-01",{"date":371,"type":38},"2024-06-20",{"date":373,"type":21},"2024-08-31",{"name":375,"class":45},"Drugs for Neglected Diseases",""]